JP2021514368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021514368A5 JP2021514368A5 JP2020543999A JP2020543999A JP2021514368A5 JP 2021514368 A5 JP2021514368 A5 JP 2021514368A5 JP 2020543999 A JP2020543999 A JP 2020543999A JP 2020543999 A JP2020543999 A JP 2020543999A JP 2021514368 A5 JP2021514368 A5 JP 2021514368A5
- Authority
- JP
- Japan
- Prior art keywords
- ligand
- nucleic acid
- treatment
- stem cell
- hematopoietic stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 48
- 150000007523 nucleic acids Chemical class 0.000 claims description 33
- 108020004707 nucleic acids Proteins 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 32
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims description 10
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims description 10
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 5
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229950007708 namilumab Drugs 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000035790 physiological processes and functions Effects 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims 14
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 230000036210 malignancy Effects 0.000 claims 9
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 238000011316 allogeneic transplantation Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950009614 gimsilumab Drugs 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- -1 -GM-CSF or -CD116 Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18158169 | 2018-02-22 | ||
| EP18158169.5 | 2018-02-22 | ||
| EP18189562 | 2018-08-17 | ||
| EP18189562.4 | 2018-08-17 | ||
| EP18194549.4 | 2018-09-14 | ||
| EP18194549.4A EP3623382A1 (en) | 2018-09-14 | 2018-09-14 | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
| US16/269,572 US11655293B2 (en) | 2018-02-22 | 2019-02-07 | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| US16/269,572 | 2019-02-07 | ||
| PCT/EP2019/054493 WO2019162472A1 (en) | 2018-02-22 | 2019-02-22 | Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514368A JP2021514368A (ja) | 2021-06-10 |
| JP2021514368A5 true JP2021514368A5 (enExample) | 2021-10-21 |
| JP7278296B2 JP7278296B2 (ja) | 2023-05-19 |
Family
ID=67616687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543999A Active JP7278296B2 (ja) | 2018-02-22 | 2019-02-22 | Ａｌｌｏ－ＨＣＴを受けた患者の血液悪性腫瘍の治療に使用するためのＧＭ－ＣＳＦまたはＧＭ－ＣＳＦ受容体のリガンド |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11655293B2 (enExample) |
| EP (1) | EP3755715A1 (enExample) |
| JP (1) | JP7278296B2 (enExample) |
| KR (1) | KR20200123434A (enExample) |
| CN (1) | CN111886248B (enExample) |
| AU (1) | AU2019224550A1 (enExample) |
| BR (1) | BR112020017253A2 (enExample) |
| CA (1) | CA3091536A1 (enExample) |
| MA (1) | MA51893A (enExample) |
| MX (2) | MX2020008792A (enExample) |
| WO (1) | WO2019162472A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
| MX2022011111A (es) * | 2020-03-08 | 2023-03-02 | Humanigen Inc | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. |
| CA3229748A1 (en) * | 2021-08-26 | 2023-03-02 | Akifumi Kato | Bispecific antibody that binds to cd116 and cd131 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1367688A (zh) | 1999-04-14 | 2002-09-04 | 美国政府卫生与公众服务部 | 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物 |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| US7741450B2 (en) * | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| MX2008012291A (es) | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| CA2717987C (en) | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| PL2643349T3 (pl) | 2010-11-26 | 2020-03-31 | Molecular Partners Ag | Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy |
| CN103827143A (zh) * | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| WO2014001442A1 (en) | 2012-06-28 | 2014-01-03 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| MA37946B1 (fr) | 2012-09-20 | 2018-09-28 | Morphosys Ag | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde |
| US9658228B2 (en) * | 2013-01-30 | 2017-05-23 | The Board of Trustees of the Leland University Junior University | Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients |
| JP6490419B2 (ja) | 2014-12-24 | 2019-03-27 | 学校法人関西医科大学 | 制御性ｔ細胞分化誘導剤 |
| US11655293B2 (en) | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
-
2019
- 2019-02-07 US US16/269,572 patent/US11655293B2/en active Active
- 2019-02-22 EP EP19705548.6A patent/EP3755715A1/en active Pending
- 2019-02-22 WO PCT/EP2019/054493 patent/WO2019162472A1/en not_active Ceased
- 2019-02-22 KR KR1020207025898A patent/KR20200123434A/ko not_active Ceased
- 2019-02-22 BR BR112020017253-7A patent/BR112020017253A2/pt not_active IP Right Cessation
- 2019-02-22 AU AU2019224550A patent/AU2019224550A1/en not_active Abandoned
- 2019-02-22 JP JP2020543999A patent/JP7278296B2/ja active Active
- 2019-02-22 MX MX2020008792A patent/MX2020008792A/es unknown
- 2019-02-22 CN CN201980020251.7A patent/CN111886248B/zh active Active
- 2019-02-22 MA MA051893A patent/MA51893A/fr unknown
- 2019-02-22 CA CA3091536A patent/CA3091536A1/en active Pending
- 2019-02-22 US US16/971,276 patent/US20210070851A1/en not_active Abandoned
-
2020
- 2020-08-21 MX MX2023001357A patent/MX2023001357A/es unknown
-
2023
- 2023-05-18 US US18/320,162 patent/US12384839B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12054557B2 (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer | |
| JP7157839B2 (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
| US20170174781A1 (en) | Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia | |
| Skorka et al. | The application of CAR-T cells in haematological malignancies | |
| Nair-Gupta et al. | A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia | |
| KR20180110141A (ko) | 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합 | |
| Hashem Boroojerdi et al. | Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia | |
| US20250304701A1 (en) | Nk engager molecules and methods of use thereof | |
| Wei et al. | Chimeric antigen receptor T-cell therapy for T-ALL and AML | |
| Xu et al. | Cellular immunotherapy for hematological malignancy: recent progress and future perspectives | |
| JP2021514368A5 (enExample) | ||
| AU2016352912A1 (en) | Modified immune cells and uses thereof | |
| Liang et al. | Insight into the progress in CAR-T cell therapy and combination with other therapies for glioblastoma | |
| JP2025166001A (ja) | 併用がん療法剤および方法 | |
| CN119816313A (zh) | 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法 | |
| CN118557714A (zh) | 用于治疗癌症的医药、组合医药、医药组合物、免疫应答细胞、核酸递送介质和制品 | |
| Bogacz et al. | Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors | |
| Elemam et al. | CAR-NK/CAR-T cells: emerging immunotherapy of cancer | |
| US20240034788A1 (en) | Abscopal therapy for cancer | |
| CA3009161C (en) | Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer | |
| WO2024148402A1 (en) | A method of preparing cells for adoptive cell therapy | |
| WO2024082025A1 (en) | Modified t cells and uses thereof | |
| Nezhad et al. | CAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens | |
| Sun et al. | Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma | |
| He et al. | Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of in vivo CAR-T platforms |